Stock Events

Infotel 

€45.8
0
+€0+0% Friday 07:04

Statistics

Day High
45.8
Day Low
45.8
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
64.37M
P/E Ratio
-
Dividend Yield
4.37%
Dividend
2

Upcoming

Dividends

4.37%Dividend Yield
10Y Growth
-5.44%
5Y Growth
4.56%
3Y Growth
7.72%
1Y Growth
N/A

Earnings

13MarExpected
Q1 2022
Q3 2022
Q4 2022
Q1 2023
Q3 2023
Q4 2023
Next
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3NH.F. It's not an investment recommendation.

About

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.
Show more...
CEO
Dr. Ronald Li B.Sc. (Hons), Ph.D.
Country
FR
ISIN
FR0000071797
WKN
000918337

Listings